Research report
A research report is the sourced material a domain
dossier is synthesized from — generated on a plan and a cadence, one topic per file.
A report carries no confidence tags. Its bracketed markers say who might have
an incentive to shade a line; none of them says anyone checked it. To reach a score, a line has
to be drafted onto a candidate as unverified and pass the Verifier or the
Corroborator, like everything else.
Section clinical-evidence · Version 2026-09-01 · Cadence quarterly · Evidence class mixed · Sources 7 · Supersedes none
Domain: potassium-monitoring-ckd · Scope: peer-reviewed and trial-registry sources reachable by this repo's connectors, WebSearch and WebFetch; a registered outcome with no results posted is a sponsor's intention, not a finding. Excludes fda.gov guidance documents (intermittent bot mitigation) and any non-US, non-EU jurisdiction.
Sourcing: one guideline document and five industry-sponsored randomized trials, cross-checked against one federal trial registry record; the trials agree in direction (potassium binders lower serum potassium and let RAASi/MRA therapy continue) but every specific effect size below comes from a single trial.
The current KDIGO guideline treats hyperkalemia during RAAS-inhibitor and mineralocorticoid receptor antagonist (MRA) titration as a problem to be managed, not a reason to stop the drug, and it specifies a monitoring cadence — potassium and creatinine rechecked within 2–4 weeks of starting or increasing a RAAS inhibitor, and regular potassium monitoring after starting a nonsteroidal MRA. The pivotal potassium-binder trials behind that stance — patiromer's OPAL-HK and sodium zirconium cyclosilicate's (SZC) HARMONIZE — both lowered serum potassium and cut hyperkalemia recurrence in randomized-withdrawal designs, and the heart-failure-specific DIAMOND trial extended the same drug class into HFrEF with a measurable reduction in hyperkalemia events and MRA dose reduction. The most recent heart-failure trial, REALIZE-K, is also the first to report a genuine caution: alongside a large effect on its primary endpoint, more patients on SZC than placebo had a cardiovascular death or worsening heart-failure event, a difference its own authors call underpowered but say should be factored into clinical decisions. None of these trials tests a monitoring device; all of them test a drug added on top of whatever monitoring regime the patient was already on.
_Baseline (v1). No prior version; this establishes the starting point for future diffs._
The KDIGO 2024 CKD guideline states the monitoring cadence directly:
"Practice Point 3.6.2: Changes in BP, serum creatinine, and serum potassium should be checked within 2–4 weeks of initiation or increase in the dose of a RASi, depending on the current GFR and serum potassium." [1] [single-source]
It pairs that cadence with an explicit preference for treating hyperkalemia over discontinuing the drug:
"Practice Point 3.6.3: Hyperkalemia associated with use of RASi can often be managed by measures to reduce the serum potassium levels rather than decreasing the dose or stopping RASi." [1] [single-source]
For nonsteroidal MRAs specifically, the same document sets monitoring as a precondition of use rather than a one-time check:
"Practice Point 3.8.3: To mitigate risk of hyperkalemia, select people with consistently normal serum potassium concentration and monitor serum potassium regularly after initiation of a nonsteroidal MRA." [1] [single-source]
The guideline's own monitoring algorithm for a nonsteroidal MRA (finerenone) schedules a potassium recheck at 1 month and then every 4 months while the drug continues — a cadence substantially wider than the 2–4-week RASi-titration window above, which the guideline attributes to the FIDELIO-DKD/FIGARO-DKD trial protocols rather than to its own independent recommendation [1] [single-source]. This report did not retrieve the 2022 AHA/ACC/HFSA heart-failure guideline's own monitoring text directly — see §5.
The two foundational binder trials both used a randomized-withdrawal design against a background of continued RAAS-inhibitor therapy, and both report the same shape of result. In OPAL-HK (chronic kidney disease, RAASi-treated, baseline potassium 5.1–<6.5 mmol/L), patiromer produced a mean potassium change of -1.01±0.03 mmol/L at 4 weeks (n=237, P<0.001), with 76% of patients reaching target (95% CI 70–81); in the subsequent 8-week randomized-withdrawal phase, hyperkalemia recurred (K+ ≥5.5 mmol/L) in 60% of the placebo group versus 15% of the patiromer group (n=107, P<0.001) [2] [single-source]. In HARMONIZE (outpatients, potassium ≥5.1 mEq/L, 44 US/Australia/ South Africa sites), SZC lowered potassium to normokalemia in a median 2.2 hours during open-label run-in, and during the 28-day randomized phase mean potassium during days 8–29 was 4.4–4.8 mEq/L across the three SZC doses versus 5.1 mEq/L on placebo (n=237, P<.001 for each dose) [3] [single-source].
DIAMOND moved the same drug class into HFrEF with current or past RAASi-related hyperkalemia. Of 1,642 patients screened, 1,195 entered a patiromer-assisted run-in to optimize RAASi/MRA dosing, and 878 (84.6%) reached target doses and were randomized (439 patiromer, 439 placebo). Over a median 27 weeks, the adjusted mean potassium change was +0.03 mmol/L with patiromer versus +0.13 mmol/L with placebo (difference -0.10 mmol/L, 95% CI -0.13 to -0.07, P<0.001); hyperkalemia
5.5 mmol/L was lower with patiromer (HR 0.63, 95% CI 0.45–0.87, P=0.006), as was MRA dose
reduction (HR 0.62, 95% CI 0.45–0.87, P=0.006), and total adjusted hyperkalemia events fell from 118.2 to 77.7 per 100 person-years (HR 0.66, 95% CI 0.53–0.81, P<0.001) [4] [single-source]. A subgroup analysis of the same run-in phase reports the mechanism behind that result directly: in patients entering with active hyperkalemia, target RAAS-inhibitor use rose from 76.8% to 98.6% and target MRA use from 35.9% to 98.6% over the run-in [5] [single-source].
REALIZE-K, the most recent HFrEF trial (spironolactone optimization with SZC), reports the largest primary-endpoint effect of any trial here — 71% of SZC-treated versus 36% of placebo-treated participants reached optimal treatment response (odds ratio 4.45, 95% CI 2.89–6.86, P<0.001), with concordant improvements on the first four hierarchical secondary endpoints (n=203 randomized) [6] [single-source]. But two results run against the drug: there was no significant difference in Kansas City Cardiomyopathy Questionnaire clinical summary score at 6 months (-1.01 points, 95% CI -6.64 to 4.63, P=0.72), and the composite of cardiovascular death or worsening heart failure occurred in 11% of the SZC group versus 3% of placebo (nominal P=0.034). The authors state the trial "was underpowered for clinical outcomes" and that "more participants had HF events with SZC than placebo, which should be factored into clinical decision making" [6] [single-source]. The trial's own ClinicalTrials.gov record confirms the design as a completed, double-blind, randomized phase 4 study with 366 participants actually enrolled overall (a larger number than the 203 carried into the published randomized-phase analysis, because enrollment spans an open-label run-in across two eligibility cohorts) [7] [single-source · sponsor-reported].
[1] KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease — Kidney International (published 2024-04; accessed 2026-09-01). PMID 38490803 — https://benhviendakhoa.gialai.gov.vn/wp-content/uploads/2024/10/CKD_2024.pdf [guideline] [2] Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors — New England Journal of Medicine (published 2015, month not given in the PubMed record; accessed 2026-09-01). PMID 25415805 — https://pubmed.ncbi.nlm.nih.gov/25415805/ [peer-reviewed] [3] Effect of Sodium Zirconium Cyclosilicate on Potassium Lowering for 28 Days Among Outpatients with Hyperkalemia: The HARMONIZE Randomized Clinical Trial — JAMA (published 2014-12-03; accessed 2026-09-01). PMID 25402495 — https://pubmed.ncbi.nlm.nih.gov/25402495/ [peer-reviewed] [4] Patiromer for the Management of Hyperkalemia in Heart Failure with Reduced Ejection Fraction: the DIAMOND Trial — European Heart Journal (published 2022, month not given in the PubMed record; accessed 2026-09-01). PMID 35900838 — https://pubmed.ncbi.nlm.nih.gov/35900838/ [peer-reviewed] [5] Patiromer Facilitates Angiotensin Inhibitor and Mineralocorticoid Antagonist Therapies in Patients with Heart Failure and Hyperkalemia — Journal of the American College of Cardiology (published 2024-10-01; accessed 2026-09-01). PMID 39322323 — https://pubmed.ncbi.nlm.nih.gov/39322323/ [peer-reviewed] [6] Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients with Heart Failure — Journal of the American College of Cardiology (published 2025-03-18; accessed 2026-09-01). PMID 39566872 — https://pubmed.ncbi.nlm.nih.gov/39566872/ [peer-reviewed] [7] Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients with Symptomatic HFrEF Receiving Spironolactone (REALIZE-K) — ClinicalTrials.gov (results posted 2025-07-09; accessed 2026-09-01). NCT04676646 — https://clinicaltrials.gov/study/NCT04676646 [trial-registry]
Well established: that a potassium binder (patiromer or SZC) lowers serum potassium and reduces hyperkalemia recurrence in patients continuing RAASi rests on two independent, non-affiliated pivotal trials of two different drugs from two different sponsors — OPAL-HK [2] and HARMONIZE [3] — which agree in direction and magnitude. That agreement is stated plainly in §1; the specific numbers behind it are still each single-trial and carry [single-source] in §3.
Thin: every specific effect size in this report — the OPAL-HK and HARMONIZE potassium changes, every DIAMOND hazard ratio and event rate, and the REALIZE-K odds ratio and event imbalance — rests on exactly one trial and is marked [single-source]. All five clinical trials cited (OPAL-HK, HARMONIZE, DIAMOND, its run-in subanalysis, and REALIZE-K) were industry-sponsored (OPAL-HK: "Funded by Relypsa," per its own abstract; REALIZE-K: sponsor AstraZeneca per its ClinicalTrials.gov record [7]); DIAMOND's and HARMONIZE's funding statements were not visible in the abstract depth this pass read. None is a manufacturer press release — all five are peer- reviewed, independently edited publications — but the funding source is a directional fact worth carrying forward rather than treating these as disinterested trials.
Rescoped from class 3: none in this report. Every proposition here is a class 1 registry record or a class 2 published trial result; nothing here answers what a clinician or patient would do.
Out of scope: the AHA/ACC/HFSA heart-failure guideline's own potassium-monitoring recommendation and its stated class-of-recommendation for patiromer/SZC use — attempted via WebFetch against jacc.org, ahajournals.org, and onlinejcf.com, all of which returned HTTP 403 — was not retrieved and is not represented anywhere in this report; the KDIGO 2024 guideline [1] is this report's only guideline source. Also out of scope: any device- or connector-based evidence (reference products, capillary/venous sampling, ECG-based screening), already covered in this domain's reference-products report and in dossier §4, is deliberately not repeated here.
Not searched vs. not found:
[inference] REALIZE-K's HF-event imbalance is read in this report as a genuine cautionary finding rather than a refutation of SZC's efficacy, because the trial's own authors describe it as underpowered and nominal rather than as a formal safety failure; a reader should weigh that authorial framing against the raw counts (11% vs. 3% of a 203-patient randomized cohort) rather than accept either reading uncritically. No source states this synthesis; it follows from reading the abstract's results and conclusions together.
Propositions a checker could attempt. This report does not append them — /research drafts them onto a candidate with engine/scripts/append_research_claims.py, which constructs the unverified tag itself.
| Proposition | Evidence class | Resolvable identifier | Dossier section |
|---|---|---|---|
| KDIGO's 2024 CKD guideline recommends rechecking blood pressure, serum creatinine, and serum potassium within 2-4 weeks of initiating or increasing a RAAS inhibitor dose | 2 published | PMID 38490803 | 4 |
| KDIGO's 2024 CKD guideline states hyperkalemia from RAASi use can often be managed by lowering potassium rather than reducing or stopping the RAAS inhibitor | 2 published | PMID 38490803 | 4 |
| Patiromer reduced mean serum potassium by 1.01 mmol/L at 4 weeks and cut hyperkalemia recurrence to 15% versus 60% on placebo in a randomized-withdrawal phase in CKD patients on RAAS inhibitors (OPAL-HK) | 2 published | PMID 25415805 | 4 |
| Sodium zirconium cyclosilicate held mean serum potassium at 4.4-4.8 mEq/L versus 5.1 mEq/L on placebo over days 8-29 of the HARMONIZE randomized phase | 2 published | PMID 25402495 | 4 |
| In the DIAMOND trial, patiromer reduced adjusted hyperkalemia events from 118.2 to 77.7 per 100 person-years versus placebo in HFrEF patients on RAASi (HR 0.66, 95% CI 0.53-0.81) | 2 published | PMID 35900838 | 4 |
| In REALIZE-K, more participants had a cardiovascular death or worsening heart failure event on sodium zirconium cyclosilicate than on placebo (11% vs 3% of 203 randomized), a nominally significant, underpowered finding | 2 published | PMID 39566872 | 4 |
| REALIZE-K was a completed, double-blind, randomized phase 4 trial sponsored by AstraZeneca with 366 participants actually enrolled | 1 registry | NCT04676646 | 4 |